检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:石月萍[1]
机构地区:[1]辽宁医学院附属第一医院中医科,锦州121001
出 处:《中国中医药现代远程教育》2014年第18期154-156,共3页Chinese Medicine Modern Distance Education of China
基 金:辽宁省自然科学基金项目[No:20111028]
摘 要:目的观察温阳通脉方对缺血再灌注大鼠心肌的保护作用及其可能机制。方法将40只SD雄性大鼠随机分为假手术组、心肌缺血再灌注损伤组(IR组)、心肌缺血预适应组(IP组)、温阳通脉方组(WY组)。建立大鼠心肌缺血再灌注损伤(IR)模型及心肌缺血预适应(IP)模型。检测各组大鼠血清心肌坏死标记物肌钙蛋白T(c Tn T)含量,免疫组化法检测心肌bax、bcl-2蛋白表达,western-blot检测akt、p-akt表达。结果 WY组、IP组血清c Tn T含量低于IR组(P驥0.05),高于假手术组(P驥0.05)。WY组、IP组bax表达低于IR组(P驥0.05)。WY组和IP组bcl-2、akt蛋白表达高于IR组(P驥0.05)。WY和IP组血清c Tn T含量及心肌bcl-2、bax、akt表达比较无统计学差异(P驦0.05)。结论温阳通脉方预处理具有心肌保护作用,其保护机制可能与激活akt通路,上调bcl-2,抑制bax蛋白表达有关。Objective To study the effect of Wenyangtongmai Decoction on rats with myocardial ischemia/reperfusion (I/R) injury and its mechanism. Methods Forty male SD rats were randomly divided into sham operation group , ischemia reperfusion (IR) group , is-chemia preconditioning (IP) group and Wenyangtongmai decoction (WY) group.The IR and IP models were established by ligation of LAD.cTnT in serum were measured.The expression of the bax and bcl-2 was tested by immunohistochemistry method.The expression of Akt was tested by Western blot method. Results The serum level of cTnT in IP and WY group were lower than IR group , but higher than sham group.The expression level of bax in IP and WY group were lower than IR group ( P〈0.05) . The expression level of akt and bcl-2 in IP and WY group were higher than IR group (P〈0.05) . but there was no difference in the serum level of cTnT and the expression level of bax , bcl-2 and akt between the two treatment groups ( P〉0.05) . Conclusion Wenyangtongmai decoction pre-conditioning can protect ischemia reperfusion rats by uploading the expression of Akt , bcl-2 and download the expression of Bax.
关 键 词:心肌缺血再灌注损伤 温阳通脉方 AKT bcl-2 BAX 胸痹
分 类 号:R259[医药卫生—中西医结合]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.38